Hazard ratios with 95% CIs for RFS, OS, CIR, and NRM according to pretransplant factors for all transplants and those in CR1
| Variable . | RFS (95% CI) . | OS (95% CI) . | CIR (95% CI) . | NRM (95% CI) . |
|---|---|---|---|---|
| All transplants | ||||
| 2008-2013 (N = 45) vs 2014-2018 (N = 36) | 2.14 (0.99-4.65), P = .052 | 2.36 (0.93-5.98), P = .07 | 2.07 (0.82-5.24), P = .13 | 1.91 (0.5-7.25), P = .34 |
| NMAC (n = 54) vs MAC (n = 27) | 0.61 (0.30-1.22), P = .16 | 0.43 (0.19-0.98), P = .045 | 0.65 (0.28-1.51), P = .32 | 0.72 (0.20-2.54), P = .61 |
| Age ≥60 y (n = 17) vs age <60 y (n = 64) | 0.97 (0.42-2.22), P = .93 | 0.73 (0.25-2.15), P = .57 | 0.70 (0.24-2.03), P = .51 | 1.66 (0.42-6.46), P = .47 |
| MRD+ Pre by MFC (n = 9) vs MRD– (n = 70) | 2.57 (1.05-6.28), P = .039 | 2.49 (1.28-4.86), P = .007 | 2.28 (0.71-7.34), P = .17 | 1.99 (0.46-8.61), P = .36 |
| MRD+ Pre by PCR (n = 9) vs MRD– (n = 50) | 1.12 (0.38-3.27), P = .84 | 1.01 (0.29-3.51), P = .99 | 1.19 (0.31-4.55), P = .80 | 0.78 (0.08-6.88), P = .82 |
| MRD+ Pre by PCR (n = 9) vs MRD–/untested (n = 72) (sensitivity analysis) | 1.18 (0.41-3.35), P = .76 | 1.13 (0.33-3.81), P = .19 | 1.19 (0.32-4.43), P = .80 | 0.89 (0.10-7.61), P = .92 |
| Donor (vs MSD (n = 16)) | ||||
| MUD (n = 16) | 0.66 (0.22-1.97), P = .46 | 0.75 (0.22-2.6), P = .65 | 1.04 (0.32-3.37), P = .95 | NA |
| Haplo (n = 47) | 0.87 (0.37-2.06), P = .75 | 0.77 (0.27-2.16), P = .62 | 0.74 (0.27-2.02), P = .55 | 1.23 (0.27-5.71), P = .79 |
| CR1 (n = 69) vs CR2+ (n = 12) | 0.25 (0.12-0.52), P = .0002 | 0.23 (0.1-0.53), P = .0006 | 0.34 (0.14-0.81), P = .015 | 0.27 (0.08-0.87), P = .03 |
| CR1 only | ||||
| TKI at Dx (vs imatinib, n = 28) | ||||
| Dasatinib (n = 33) | 0.21 (0.07-0.66), P = .007 | 0.16 (0.06-0.75), P = .02 | 0.29 (0.08-1.03), P = .06 | 0.16 (0.02-1.35), P = .09 |
| Nilotinib (n = 8) | 0.75 (0.22-2.6), P = .66 | 0.66 (0.14-2.99), P = .59 | 1.34 (0.33-5.49), P = .69 | NA |
| NMAC (n = 43) vs MAC (n = 26) | 0.37 (0.16-0.88), P = .02 | 0.15 (0.04-0.53), P = .0035 | 0.48 (0.18-1.3), P = .15 | 0.29 (0.06-1.56), P = .15 |
| Age ≥60 y (n = 14) vs age <60 y (n = 55) | 1.14 (0.42-3.11), P = .79 | 0.63 (0.14-2.83), P = .55 | 0.82 (0.24-2.77), P = .75 | 2.06 (0.38-11.32), P = .41 |
| MRD+ Pre by MFC (n = 6) vs MRD– (n = 62) | 3.65 (1.22-10.9), P = .02 | 5.63 (1.74-18.2), P = .004 | 3.55 (0.94-13.3), P = .06 | 2.09 (0.28-15.74), P = .48 |
| MRD+ Pre by PCR (n = 7) vs MRD– (n = 43) | 0.75 (0.17-3.32), P = .71 | 0.61 (0.08-4.86), P = .64 | 0.43 (0.05-3.62), P = .44 | 2.13 (0.21-21.11), P = .52 |
| MRD+ Pre by PCR (n = 7) vs MRD–/untested (n = 62) (sensitivity analysis) | 0.82 (0.19-3.5), P = .79 | 0.62 (0.08-4.77), P = .65 | 0.49 (0.06-4.15), P = .52 | 1.85 (0.21-16.5), P = .58 |
| Donor (vs MSD, n = 16) | ||||
| MUD (n = 13) | 0.37 (0.1-1.43), P = .15 | 0.36 (0.07-1.88), P = .23 | 0.57 (0.14-2.3), P = .43 | NA |
| Haplo (n = 38) | 0.64 (0.25-1.63), P = .35 | 0.51 (0.16-1.62), P = .26 | 0.61 (0.21-1.78), P = .37 | 0.81 (0.16-4.2), P = .8 |
| 2008-2013 (N = 37) vs 2014-2018 (N = 32) | 2.75 (1.00-7.52), P = .05 | 2.14 (0.67-6.84), P = .20 | 3.23 (0.92-11.3), P = .07 | 1.74 (0.33-9.28), P = .52 |
| Variable . | RFS (95% CI) . | OS (95% CI) . | CIR (95% CI) . | NRM (95% CI) . |
|---|---|---|---|---|
| All transplants | ||||
| 2008-2013 (N = 45) vs 2014-2018 (N = 36) | 2.14 (0.99-4.65), P = .052 | 2.36 (0.93-5.98), P = .07 | 2.07 (0.82-5.24), P = .13 | 1.91 (0.5-7.25), P = .34 |
| NMAC (n = 54) vs MAC (n = 27) | 0.61 (0.30-1.22), P = .16 | 0.43 (0.19-0.98), P = .045 | 0.65 (0.28-1.51), P = .32 | 0.72 (0.20-2.54), P = .61 |
| Age ≥60 y (n = 17) vs age <60 y (n = 64) | 0.97 (0.42-2.22), P = .93 | 0.73 (0.25-2.15), P = .57 | 0.70 (0.24-2.03), P = .51 | 1.66 (0.42-6.46), P = .47 |
| MRD+ Pre by MFC (n = 9) vs MRD– (n = 70) | 2.57 (1.05-6.28), P = .039 | 2.49 (1.28-4.86), P = .007 | 2.28 (0.71-7.34), P = .17 | 1.99 (0.46-8.61), P = .36 |
| MRD+ Pre by PCR (n = 9) vs MRD– (n = 50) | 1.12 (0.38-3.27), P = .84 | 1.01 (0.29-3.51), P = .99 | 1.19 (0.31-4.55), P = .80 | 0.78 (0.08-6.88), P = .82 |
| MRD+ Pre by PCR (n = 9) vs MRD–/untested (n = 72) (sensitivity analysis) | 1.18 (0.41-3.35), P = .76 | 1.13 (0.33-3.81), P = .19 | 1.19 (0.32-4.43), P = .80 | 0.89 (0.10-7.61), P = .92 |
| Donor (vs MSD (n = 16)) | ||||
| MUD (n = 16) | 0.66 (0.22-1.97), P = .46 | 0.75 (0.22-2.6), P = .65 | 1.04 (0.32-3.37), P = .95 | NA |
| Haplo (n = 47) | 0.87 (0.37-2.06), P = .75 | 0.77 (0.27-2.16), P = .62 | 0.74 (0.27-2.02), P = .55 | 1.23 (0.27-5.71), P = .79 |
| CR1 (n = 69) vs CR2+ (n = 12) | 0.25 (0.12-0.52), P = .0002 | 0.23 (0.1-0.53), P = .0006 | 0.34 (0.14-0.81), P = .015 | 0.27 (0.08-0.87), P = .03 |
| CR1 only | ||||
| TKI at Dx (vs imatinib, n = 28) | ||||
| Dasatinib (n = 33) | 0.21 (0.07-0.66), P = .007 | 0.16 (0.06-0.75), P = .02 | 0.29 (0.08-1.03), P = .06 | 0.16 (0.02-1.35), P = .09 |
| Nilotinib (n = 8) | 0.75 (0.22-2.6), P = .66 | 0.66 (0.14-2.99), P = .59 | 1.34 (0.33-5.49), P = .69 | NA |
| NMAC (n = 43) vs MAC (n = 26) | 0.37 (0.16-0.88), P = .02 | 0.15 (0.04-0.53), P = .0035 | 0.48 (0.18-1.3), P = .15 | 0.29 (0.06-1.56), P = .15 |
| Age ≥60 y (n = 14) vs age <60 y (n = 55) | 1.14 (0.42-3.11), P = .79 | 0.63 (0.14-2.83), P = .55 | 0.82 (0.24-2.77), P = .75 | 2.06 (0.38-11.32), P = .41 |
| MRD+ Pre by MFC (n = 6) vs MRD– (n = 62) | 3.65 (1.22-10.9), P = .02 | 5.63 (1.74-18.2), P = .004 | 3.55 (0.94-13.3), P = .06 | 2.09 (0.28-15.74), P = .48 |
| MRD+ Pre by PCR (n = 7) vs MRD– (n = 43) | 0.75 (0.17-3.32), P = .71 | 0.61 (0.08-4.86), P = .64 | 0.43 (0.05-3.62), P = .44 | 2.13 (0.21-21.11), P = .52 |
| MRD+ Pre by PCR (n = 7) vs MRD–/untested (n = 62) (sensitivity analysis) | 0.82 (0.19-3.5), P = .79 | 0.62 (0.08-4.77), P = .65 | 0.49 (0.06-4.15), P = .52 | 1.85 (0.21-16.5), P = .58 |
| Donor (vs MSD, n = 16) | ||||
| MUD (n = 13) | 0.37 (0.1-1.43), P = .15 | 0.36 (0.07-1.88), P = .23 | 0.57 (0.14-2.3), P = .43 | NA |
| Haplo (n = 38) | 0.64 (0.25-1.63), P = .35 | 0.51 (0.16-1.62), P = .26 | 0.61 (0.21-1.78), P = .37 | 0.81 (0.16-4.2), P = .8 |
| 2008-2013 (N = 37) vs 2014-2018 (N = 32) | 2.75 (1.00-7.52), P = .05 | 2.14 (0.67-6.84), P = .20 | 3.23 (0.92-11.3), P = .07 | 1.74 (0.33-9.28), P = .52 |
CI, confidence interval; CIR, cumulative incidence of relapse; Dx, diagnosis; NA, not applicable; Pre, pretransplant.